2011-04-18T14:27:05-05:00 2010-06-30 Clark Nuber PS 10900 NE 4th Street Suite 1700 Bellevue WA 98004 990 2009-07-01 910961784 SEATTLE BIOMEDICAL RESEARCH INSTITUTE SEAT 2062567200 307 WESTLAKE AVENUE NORTH No 500 SEATTLE WA 981095219 RANDAL HASSLER 2062567200 2011-04-13 1 Jane M Searing 4254544919 2009 2016-02-24 21:20:13Z SEATTLE BIOMED Randal Hassler 307 WESTLAKE AVENUE NORTH No 500 SEATTLE WA 981095219 60752449 0 X www.seattlebiomed.org X 1976 WA TO ELIMINATE THE WORLD'S MOST DEVASTATING INFECTIOUS DISEASES. 25 25 341 145 159149 156449 43234968 46090916 444873 239657 283901 276722 2350530 2340654 46314272 48947949 0 0 14954134 17513847 0 708079 29521330 33076016 44475464 50589863 1838808 -1641914 41478368 37706828 20289807 17761031 21188561 19945797 CONDUCT RESEARCH LEADING TO THE PREVENTION, DIAGNOSIS AND CURE OF GLOBAL HEALTH INFECTIOUS DISEASES INCLUDING MALARIA, HIV/AIDS AND TB. DISEASES RESPONSIBLE FOR THE DEATHS OF 14 MILLION EACH YEAR. 0 0 19524180 104612 MALARIA: THE STUDY OF THIS COMPLEX PARASITE HAS LED SEATTLE BIOMED RESEARCHERS TO FUNDAMENTAL DISCOVERIES OF THE GENETIC FRAMEWORK AND MOLECULAR BIOLOGY OF THE MOST VIRULENT MALARIA PARASITE, PLASMODIUM FALCIPARUM. SEATTLE BIOMED RESEARCHERS ARE FOCUSED ON DEVELOPING NEW VACCINES AND DRUGS FOR EARLY STAGE MALARIA, SEVERE MALARIA IN CHILDREN AND PREGNANCY MALARIA. SEATTLE BIOMED HOUSES A MALARIA CLINICAL TRIALS CENTER - ONE OF ONLY FOUR FACILITIES OF ITS KIND WORLDWIDE - TO SAFELY AND EFFECTIVELY TEST TREATMENTS IN HUMANS. SEATTLE BIOMED HAS SIX PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 13731862 73576 EMERGING INFECTIONS AND TB: IN THE FIELD OF FUNGAL INFECTIONS, SEATTLE BIOMED HAS MADE A NUMBER OF CRITICAL DISCOVERIES THAT CAST LIGHT ON THE CELLULAR EFFECTS OF DRUG RESISTANCE AND ON BASIC MECHANISMS THAT TRIGGER THE ONSET AND VIRULENCE OF CANDIDIASIS AND OTHER INFECTIONS. WITH EXPERTISE IN THE PATHOGENESIS OF TUBERCULOSIS, SEATTLE BIOMED RESEARCHERS ARE FOCUSED ON ELIMINATING THE BIOLOGICAL BARRIERS TO TB DRUG DISCOVERY AND SHORTENING THE COURSE OF TREATMENT FROM SIX MONTHS TO TWO WEEKS. SEATTLE BIOMED SCIENTISTS HAVE ALSO TURNED TO IMMUNOLOGY TO SHARPEN THEIR FOCUS ON THE HOST PERSPECTIVE OF DISEASE; WITH A BETTER UNDERSTANDING OF HOW TB IS ABLE TO EVADE THE IMMUNE SYSTEM, NEW THERAPIES CAN BE TESTED. SEATTLE BIOMED HAS FOUR PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 7284955 39033 HIV/AIDS: VACCINE DEVELOPMENT IS THE TARGET OF SEATTLE BIOMED'S HIV/AIDS RESEARCH. OUR RESEARCHERS ARE DEVELOPING NOVEL APPROACHES TO DESIGNING VACCINE CANDIDATES THAT INCLUDE ANTI-HIV NEUTRALIZING ANTIBODIES. AND, WE'RE COMPARING HUNDREDS OF VACCINE CANDIDATES TO IDENTIFY THOSE MOST LIKELY TO SUCCEED IN CLINICAL TRIALS. SEATTLE BIOMED HAS THREE PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 3254547 17438 TRYPANOSOMES: BY FOCUSING ON THE TRYPANOSOMATID DISEASES, WE'RE UNCOVERING SPECIFIC PROCESSES AND GENE FUNCTION TO BETTER TARGET NEW DRUGS AND DIAGNOSTICS TO PREVENT AFRICAN SLEEPING SICKNESS, CHAGAS' DISEASE AND LEISHMANIASIS. SEATTLE BIOMED HAS THREE PRINCIPAL INVESTIGATORS COMMITTED TO THIS RESEARCH. 932585 4998 BIOQUEST: THE PRIMARY GOAL OF SEATTLE BIOMED SCIENCE OUTREACH PROGRAM, BIOQUEST, IS TO PROVIDE A CURRICULUM-RELEVANT, CAREER-INSPIRING, TECHNOLOGY-RICH SCIENCE EDUCATION PROGRAM WITHIN THE CONTEXT OF INFECTIOUS DISEASE RESEARCH TO HIGH SCHOOL STUDENTS, TEACHERS AND THE GENERAL PUBLIC. WE ARE THE ONLY ORGANIZATION IN THE NATION TO OFFER A 32-PERSON TEACHING LAB, WITHIN THE FOOTPRINT OF AN INFECTIOUS DISEASE RESEARCH INSTITUTE. 4187132 22436 44728129 1 1 0 1 0 0 0 0 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 50 0 1 341 1 1 1 1 TZ 0 0 0 1 1 0 0 0 25 25 1 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 WA X X RANDAL HASSLER 2062567200 307 WESTLAKE AVE N 500 Seattle WA 981095219 TODD PATRICK 5.00 X X 0 0 0 TREVOR MOODY 5.00 X X 0 0 0 MIKE STULL 5.00 X X 0 0 0 DARRYL JOHNSON 5.00 X X 0 0 0 MAUD DAUDON 5.00 X 0 0 0 GLORIA PFEIF 5.00 X 0 0 0 JAMES A JOHNSON 5.00 X 0 0 0 ALAN LEVY 5.00 X 0 0 0 BONNIE TOWNE 5.00 X 0 0 0 BRUCE EASTER 5.00 X 0 0 0 CAROL BRYAN 5.00 X 0 0 0 CAROL LEWIS 5.00 X 0 0 0 CHRISTOPHER H PORTER 5.00 X 0 0 0 DEAN ALLEN 5.00 X 0 0 0 ERICK RABINS 5.00 X 0 0 0 GREG SIMON 5.00 X 0 0 0 J PAUL BLAKE 5.00 X 0 0 0 JAMES DAVIE 5.00 X 0 0 0 JANE A BIDDLE 5.00 X 0 0 0 JANE HEDREEN 5.00 X 0 0 0 JOE CERRELL 5.00 X 0 0 0 KATHERINE M LOMBARDO 5.00 X 0 0 0 MARLYN FRIEDLANDER 5.00 X 0 0 0 MOYA VAZQUEZ 5.00 X 0 0 0 ROSEMARY BARKER ARAGON 5.00 X 0 0 0 TERRENCE R MEERSMAN 5.00 X 0 0 0 USHA VARANASI 5.00 X 0 0 0 VINCENT BRYAN 5.00 X 0 0 0 GREGG BLODGETT 5.00 X 0 0 0 NEIL MCDONNELL 5.00 X 0 0 0 KRIS RICHEY 5.00 X 0 0 0 MELISSA YEAGER 5.00 X 0 0 0 DR KENNETH STUART 40.00 X 276587 0 32943 RANDAL HASSLER 40.00 X 174693 0 27401 PATRICK DUFFY 40.00 X 226719 0 20060 MICHAEL PODLIN 40.00 X 173848 0 21914 LYNN ZIMMERMAN 40.00 X 127360 0 16826 MARILYN PARSONS 40.00 X 165943 0 24891 ANGELA TALLEY 40.00 X 136627 0 16947 IAN CRISPE 40.00 X 172244 0 25479 STEFAN KAPPE 40.00 X 134936 0 16001 1588957 0 202462 20 0 1 0 LEASE CRUTCHER LEWIS WA LLC 107 SPRING STREET SEATTLE WA 981041052 BUILDING ALTERATIONS 1143882 JILL A SUMMIT 7520 18TH AVE NE SEATTLE WA 98115 CONTRACT ACCOUNTING 128337 CHRISTENSEN O'CONNOR JOHNSON KINDNESS 1420 FIFTH AVE SUITE 2800 SEATTLE WA 981012347 LEGAL SERVICES 121364 LAURA J COLLINS PHD 15007 61ST DR SE SNOHOMISH WA 98298 CONSULTING SERVICES 114130 4 270454 23723086 22097376 46090916 RESEARCH SUPPORT SRVCS 900099 115064 115064 EDUCATION PROGRAM 900099 112918 112918 Program Service Fees 900099 11675 11675 239657 291876 291876 2474921 76389 2398532 2398532 159149 2239383 11600000 10000 11600000 25154 0 -15154 -15154 -15154 42525 270454 102957 -60432 -60432 FLEX PLAN FORFEITURES 900099 1654 1654 US TREASURY REFUND 900099 700 700 NYU HONORARIUM 900099 200 200 2554 48947949 239657 159149 2458227 954166 840354 88908 24904 13250907 11670098 1234337 346472 892755 786402 83038 23315 1331454 1172841 123842 34771 1084565 955364 100878 28323 230216 190420 37099 2697 78551 5534 72854 163 129472 107091 20864 1517 25692 10268 12917 2507 4583310 3850458 678405 54447 11165 8450 2715 1227005 1085984 119186 21835 235098 210587 22118 2393 5725334 3719082 1972312 33940 344650 306288 25333 13029 306305 272212 22514 11579 280442 273496 4595 2351 1916725 1780241 124196 12288 237877 74122 163755 SUBCONTRACTS 13223682 13223682 RESEARCH SUPPLIES 3152809 3152809 NON EMPLOYEE PERSONNEL 827188 823271 3892 25 UBIT 72840 72840 BAD DEBTS 67420 6919 60501 400235 210606 161322 28307 50589863 44728129 5153655 708079 3396244 6395094 8198463 12642802 6077828 6256508 130649 74404 174627 258327 98482 61270 49042 342687 306940 22824570 11889674 10691334 10934896 11600000 263963 405825 457603 368208 41478368 37706828 5848727 4593542 8813760 8375988 4404992 3481384 1222328 1310117 20289807 17761031 X 10541457 13295192 10597104 6600605 50000 50000 21188561 19945797 41478368 37706828 X 0 1 1 X 1 1 X UNIVERSITY OF WASHINGTON MEDICAL CENTER SEATTLE WA WALTER REEDY ARMY INSTITUTE OF RESEARCH SILVER SPRING MD MOROGORO REGIONAL HOSPITAL MOROGORO TZ RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 129472 0 0 129472 0 50000 50000 50000 50000 0.00000 1.00000 0.00000 0 0 20503 20503 0 11143105 3892365 7250740 10793651 7326755 3466896 867311 650051 217260 10934896 FAIR VALUE OF INTEREST RATE SWAP 190692 DEFERRED RENT LIABILITY 1119425 1310117 48947949 50589863 -1641914 399150 399150 -1242764 49372253 52652 52652 49319601 -371652 -371652 48947949 50615017 25154 25154 50589863 0 50589863 Part V, Line 4: Description of Intended Use of Endowment Funds: WE CONTINUE TO REINVEST FOR UNRESTRICTED EARNINGS. Part XI, Line 8 - Other Adjustments: CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT: 52652. BOOK/TAX DIFFERENCE ON INVESTMENT IN 307 WESTLAKE: 346498. Part XII, Line 2d - Other Adjustments: CHANGE IN FAIR MARKET VALUE OF INTEREST RATE SWAP: 52652. Part XII, Line 4b - Other Adjustments: BOOK/TAX DIFFERENCE FROM INVESTMENT IN 307 WESTLAKE: -346498. LOSS ON DISPOSAL OF FIXED ASSETS: -25154. Part XIII, Line 2d - Other Adjustments: LOSS ON SALE OF FIXED ASSETS: 25154. East Asia and the Pacific 0 0 Program Services subcontractor 463946 Europe 0 0 Program Services subcontractor 1800821 South Asia 0 0 Program Services subcontractor 47912 Sub-Saharan Africa 0 0 Program Services subcontractor 799260 SUB-Saharan Africa 0 0 PROGRAM SERVICES CONSULTANTS 95065 SUB-Saharan Africa 0 0 PROGRAM SERVICES MEETING EXPENSES 13607 SOUTH ASIA 0 0 PROGRAM SERVICES MEETING EXPENSES 16185 NORTH AMERICA 0 0 PROGRAM SERVICES CONSULTANTS 6390 0 0 3243186 PASSPORT DINNER 312979 270454 42525 33000 41879 4000 24078 312979 270454 42525 33000 41879 4000 24078 102957 -60432 X X X X 0 0 0 0 0 0 0 0 0 DR KENNETH STUART 273018 0 3569 0 0 0 28998 0 3945 0 309530 0 0 0 RANDAL HASSLER 174693 0 0 0 0 0 18000 0 9401 0 202094 0 0 0 PATRICK DUFFY 226719 0 0 0 0 0 15942 0 4118 0 246779 0 0 0 MICHAEL PODLIN 173848 0 0 0 0 0 17500 0 4414 0 195762 0 0 0 MARILYN PARSONS 165943 0 0 0 0 0 18169 0 6722 0 190834 0 0 0 ANGELA TALLEY 136627 0 0 0 0 0 9744 0 7203 0 153574 0 0 0 IAN CRISPE 172244 0 0 0 0 0 19708 0 5771 0 197723 0 0 0 STEFAN KAPPE 134936 0 0 0 0 0 9450 0 6551 0 150937 0 0 0 IAN CRISPE X 80000 82598 0 1 1 STEFAN KAPPE X 80000 92029 0 1 1 174627 Form 990, Part VI, Section A, line 2 CAROL BRYAN AND VINCENT BRYAN - FAMILY RELATIONSHIP. Form 990, Part VI, Section A, line 4 WE OFFICIALLY CHANGED OUR STATUS TO A MEDICAL RESEARCH ORGANIZATION DURING THE CURRENT FISCAL YEAR. Form 990, Part VI, Section B, line 11 THE RETURN WILL BE REVIEWED IN DETAIL BY THE DIRECTOR OF FINANCE. AFTER REVIEW, A FINAL DRAFT OF FORM 990 WILL BE ELECTRONICALLY CIRCULATED TO ALL TRUSTEES OF SEATTLE BIOMED. OUR BOARD LIAISON WILL MONITOR, IN WRITING, THE RECEIPT OF FORM 990 TO TRUSTEES; COLLECT ANY COMMENTS AND RESPONSES; AND REPORT THESE TO THE CONTROLLER IN A TIMELY FASHION. ANY PERTINENT RESPONSES WILL BE ADDRESSED AND RESOLVED BEFORE OUR FINAL TAX RETURN IS FILED. Form 990, Part VI, Section B, line 12c EACH TRUSTEE (AND ALL KEY EMPLOYEES) AND MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT SUCH PERSON HAS RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY, HAS READ AND UNDERSTANDS THE POLICY, AND AGREES TO COMPLY WITH THE POLICY. IF ANY KNOWN CONFLICTS ARISE, THEY ARE SENT TO THE EXECUTIVE COMMITTEE FOR RESOLUTION. A FOLLOWUP TO THE LEADERSHIP TEAM THEN OCCURS, IF NEEDED. PROCEDURES: 1. DUTY TO DISCLOSE: IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE AND NATURE OF HIS/HER FINANCIAL INTEREST TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES PRIOR TO CONSIDERATION OF THE PROPOSED TRANSACTION OR ARRANGEMENT AND MUST NOT ENTER INTO ANY ARRANGEMENT WHERE THERE IS AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST WITHOUT EXECUTIVE COMMITTEE APPROVAL. 2. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST, THE INTERESTED PERSON SHALL RECUSE HIMSELF/HERSELF WHILE THE FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE EXECUTIVE COMMITTEE SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. 3. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. THE EXECUTIVE COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. B. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER SEATTLE BIOMED CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. C. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED MEMBERS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN SEATTLE BIOMED'S BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO SEATTLE BIOMED AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. 4. VIOLATIONS OF THE CONFLICTS OF INTEREST POLICY: A.IF THE BOARD, A COMMITTEE, SEATTLE BIOMED STAFF OR A TRUSTEE HAS REASONABLE CAUSE TO BELIEVE THAT A TRUSTEE OR A COMMITTEE MEMBER HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OF THE BASIS FOR SUCH BELIEF AND AFFORD THE MEMBER THE OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF THE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE EXECUTIVE BOARD DETERMINES THAT THE MEMBER HAS, IN FACT, FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. Form 990, Part VI, Section B, line 15 COMPENSATION PLANNING AND REVIEW TAKES PLACE ANNUALLY IN NOVEMBER OR DECEMBER FOR JANUARY 1 SALARY CHANGES. HUMAN RESOURCES PROVIDES MARKET DATA FOR EACH POSITION IN THE INSTITUTE. FOR SENIOR LEADERSHIP POSITIONS, SPECIFICALLY KEY EMPLOYEES, AN OUTSIDE COMPENSATION CONSULTANT BENCHMARKS THESE POSITIONS AND PROVIDES THE DATA AND ANALYSIS, WHICH ALLOWS US TO ESTABLISH A PAY RANGE FOR EACH OF THESE ROLES AT OUR INSTITUTE. WE ALSO GATHER INDUSTRY SPECIFIC INFORMATION FROM OUR PEERS TO VALIDATE THE SURVEY INFORMATION AND TO ENSURE THAT WE REMAIN COMPETITIVE WITH OUR COMPENSATION. THIS INFORMATION IS SOMETIMES GATHERED FROM LOCAL PEER ORGANIZATIONS IN OUR INDUSTRY AND/OR FROM PEER ORGANIZATIONS WHO ARE PART OF THE ASSOCIATE OF INDEPENDENT RESEARCH INSTITUTES (AIRI). ANNUALLY, AS PART OF THE PLANNING PROCESS, THE LEADERSHIP GROUP AT SEATTLE BIOMED, ESTABLISHES AN AVERAGE INCREASE PERCENTAGE AND OVERALL BUDGET. WE TAKE INTO CONSIDERATION THE ECONOMIC CONDITIONS, THE INSTITUTE'S ABILITY TO PAY, AND THE COMPETITIVE LANDSCAPE (WE SPECIFICALLY BENCHMARK WHAT OUR PEER ORGANIZATIONS ARE PLANNING FOR INCREASES). WE HOLD IN RESERVE A SMALL PERCENTAGE OF BUDGET TO PROVIDE MARKET ADJUSTMENT INCREASES OR EXTRAORDINARY PERFORMANCE INCREASES. WE APPLY THE SAME METHODOLOGY ACROSS THE INSTITUTE, FOR ALL POSITIONS. BASED ON THE MARKET INFORMATION AND THE INSTITUTE SPECIFIC BUDGET, HUMAN RESOURCES MEETS WITH SEATTLE BIOMED'S PRESIDENT TO PLAN FOR COMPENSATION CHANGES FOR ALL OF HIS DIRECT REPORTS, INCLUDING PRIMARY INVESTIGATORS AND VICE PRESIDENTS. REGARDING THE PRESIDENT'S COMPENSATION, THE DIRECTOR OF HUMAN RESOURCES PROVIDES THE SEATTLE BIOMED BOARD CHAIR WITH MARKET SURVEY DATA AND ANALYSIS DEVELOPED BY AN EXTERNAL COMPENSATION CONSULTANT, AS WELL AS OTHER RELEVANT INFORMATION AND A PROPOSED INCREASE. THE BOARD CHAIR IDENTIFIES A SUB COMMITTEE OF THE BOARD TO REVIEW THE COMPENSATION DATA AND APPROVE ANY COMPENSATION CHANGES FOR THE PRESIDENT. Form 990, Part VI, Section C, line 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART I, LINE 6 THERE WERE 38 SEATTLE BIOMED SCIENTISTS WHO VOLUNTEERED 65 HOURS AND 19 PEOPLE WHO VOLUNTEERED 310 HOURS TO BIOQUEST PROGRAM. THERE WERE 56 PASSPORT VOLUNTEERS, INCLUDING 6 EXTERNAL PEOPLE WHO VOLUNTEERED 120 HOURS AND 50 INTERNAL PEOPLE WHO VOLUNTEERED 200 HOURS. THERE WERE 32 VOLUNTEERS SERVING AS BOARD MEMBERS DURING THE YEAR.